[Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].
Today 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are the most often prescribed drugs among the therapeutics for hypercholesterolemia. Pitavastatin is a novel statin that has been developed entirely in Japan from the biological screening to clinical studies persuing more efficatious statin than hitherto known. Preclinical studies on drug metabolism revealed that pitavastatin is distributed selectively to the liver, excreted into bile without metabolic modification, and efficiently re-circulates to the liver to show a prolonged plasma half-life. In guinea pigs, pitavastatin enhanced hepatic LDL receptor activity and reduced VLDL secretion in a liver perfusion study, and it lowered plasma total cholesterol (TC) levels at 0.3 mg/kg and triglyceride (TG) levels at 1 mg/kg, respectively, and more. From these results, pitavastatin is assumed to lower LDL cholesterol (LDL-C) by promoting LDL receptor expression and further potentiate the cholesterol-lowering effect and exert TG-lowering effect by reducing VLDL secretion. (14)C-Pitavastatin is metabolized with CYP2C9 to 8-hydroxy derivative, but its Vmax /Km was about 2 micro l/min/mg, about 1/8 to 1/100 in comparison to the reported values of other statins, indicating that pitavastatin is hardly metabolized. Also, other human P450 species were not inhibited by pitavastatin. Therefore, pitavastatin is considered to have little interaction with drugs through P450. In the summarized clinical results with 862 patients, pitavastatin lowered TC and LDL-C by 28% and 40%, respectively. There was no difference in the frequency of side effects and no serious adverse effect was observed for pitavastatin. Pitavastatin possesses superior plasma lipid-improving effects, induces little drug interaction, and is expected to make a good contribution to the medication of hypercholesterolemia.
Yamazaki
Hiroyuki
H
Atherosclerosis Research Dept., Tokyo New Drug Research Laboratories I, Kowa Company, Ltd., Higashimurayama, Tokyo, Japan.
Fujino
Hideki
H
Kanazawa
Mizuho
M
Tamaki
Taro
T
Sato
Fumiyasu
F
Suzuki
Mikio
M
Kitahara
Masaki
M
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000517:prevention & control; D002784:Cholesterol / Q000096:biosynthesis; D015243:Cholesterol, VLDL / Q000378:metabolism; D032083:Citrus paradisi; D002986:Clinical Trials as Topic; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D011345:Fenofibrate / Q000627:therapeutic use; D018565:Food-Drug Interactions; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011804:Quinolines / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011973:Receptors, LDL / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
D015243:Cholesterol, VLDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; D011973:Receptors, LDL; D014280:Triglycerides; D003577:Cytochrome P-450 Enzyme System; D002784:Cholesterol; C108475:pitavastatin; D011345:Fenofibrate